ToxStrategies Acquires Clintrex Research Corporation
June 25, 2024
ToxStrategies, a Renovus Capital Partners–backed scientific consulting firm based in Katy, Texas, has acquired Clintrex Research Corporation, a Sarasota-based clinical and regulatory development services provider focused on neurodegenerative and CNS therapies. The deal (terms undisclosed) expands ToxStrategies' clinical, regulatory, biostatistics and drug‑development capabilities and is intended to broaden its end‑market reach in the life sciences sector.
- Targets
- Clintrex Research Corporation
- Platforms
- ToxStrategies
- Industry
- Healthcare Services
- Location
- Florida, United States
- Transaction Type
- Addon
Explore More
Related Acquisitions
-
Tarsus Pharmaceuticals Acquires iRenix Medical to Advance IRX-101 for Retina Care
July 9, 2026
Biotechnology
Tarsus Pharmaceuticals announced it has acquired iRenix Medical, adding late-stage investigational ocular antiseptic IRX-101 to its eye care pipeline. Under the agreement, Tarsus will pay about $75 million upfront (cash and stock) and make additional regulatory and commercial milestone payments up to $490 million.
-
Renovus-Backed BlueRidge Life Sciences Formed by Uniting Suttons Creek, Modality Solutions, CLINTREX and ToxStrategies
August 25, 2025
Healthcare Services
Four life-sciences consulting firms — Suttons Creek, Modality Solutions, CLINTREX, and ToxStrategies — have been unified under the new brand BlueRidge Life Sciences to create an integrated life-sciences services platform. The move, backed by private equity sponsor Renovus Capital Partners, consolidates toxicology, regulatory science, engineering, clinical research and related capabilities to offer end-to-end scientific and regulatory support to pharmaceutical, biotech, medical device and consumer-product clients.
-
ToxStrategies Acquires Suttons Creek
August 13, 2024
Healthcare Services
ToxStrategies, a Renovus Capital Partners portfolio company, has acquired Suttons Creek to expand its combination-product development and regulatory consulting capabilities. Brookside Capital Partners provided financing to support the add-on acquisition; Suttons Creek will operate as a division of ToxStrategies and its founder Steven Badelt will continue to lead the business. Terms were not disclosed.
-
ToxStrategies (Renovus-backed) Acquires Modality Solutions
August 8, 2023
Healthcare Services
ToxStrategies, a Renovus Capital Partners-backed life sciences consulting platform, has acquired Modality Solutions, a Houston-based firm specializing in biopharmaceutical cold-chain optimization and shipping validation testing. The add-on expands ToxStrategies' cold-chain, package engineering, and regulatory testing capabilities and will operate as a division of ToxStrategies with Modality's founders continuing to lead the business.
-
Renovus Capital Partners Majority Investment in ToxStrategies
January 24, 2023
Healthcare Services
Renovus Capital Partners made a majority investment in ToxStrategies, a multidisciplinary scientific consulting firm specializing in toxicology, epidemiology, exposure sciences and regulatory compliance. Five Points Capital provided debt and equity co-investment to support the transaction; terms were not disclosed and the deal was described as a recapitalization to support growth and expand services, staff and geographic reach.
-
Labcorp Acquires Toxikon Corporation
November 18, 2021
Healthcare Services
Labcorp has acquired Toxikon Corporation, a Bedford, Massachusetts-based contract research organization that provides nonclinical in vivo and in vitro testing for pharmaceutical, biotech and medical device clients. The acquisition expands Labcorp Drug Development's nonclinical testing capabilities and creates a strategic Boston-area footprint; Toxikon reported approximately $40 million in annual revenue and the deal closed in December 2021.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.